The future of diabetes care may not be about better insulin.
It may be about making insulin easier to live with.
When we talk about pharmaceutical innovation, we often think about discovering new molecules or developing more effective therapies.
But there’s another kind of innovation that deserves just as much attention:
Reducing the burden of treatment.
For someone living with diabetes, the challenge isn’t only controlling blood sugar.
It’s also the routine that comes with it.
Daily injections.
Daily planning.
Daily reminders.
Over time, even an effective treatment can become difficult to sustain.
That’s why the recent introduction of Awiqli® (Insulin Icodec) in India caught my attention.
Not because it’s “just another insulin.”
But because it reflects a shift in how we think about patient care.
Instead of requiring a basal insulin injection every day, Awiqli is designed to provide week-long basal insulin coverage with a single weekly dose.
The innovation isn’t simply reducing 365 injections to 52.
It’s reducing the day-to-day burden that comes with long-term therapy.
And that matters because better treatment isn’t only measured by clinical efficacy.
It’s also measured by whether patients can realistically continue taking it over the long term.
Of course, this isn’t a cure for diabetes, and it won’t be the right choice for every patient.
But it represents something bigger:
A move toward designing treatments that fit more naturally into people’s lives.
As someone with a background in pharmacology, I believe the next wave of healthcare innovation won’t be defined only by how well medicines work.
It will also be defined by how easily patients can live with them.
Because sometimes…
improving the patient experience is one of the most meaningful innovations in medicine.
What do you think will shape the future of chronic disease management more—better medicines or treatments that are easier for patients to follow consistently?
MBH/PS